Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed.
We undertook comparisons of Dako 28-8 and Ventana SP142 assays in mRCC and Dako 22C3 and Ventana SP263 assays in mUC.
Thirty-two patients with mRCC and 18 patients with mUC who had received immune checkpoint inhibitor therapy were identified. Formalin-fixed paraffin-embedded tumor samples for patients with mRCC were evaluated with Dako 28-8 and Ventana SP142 PD-L1 immunohistochemistry assays. For patients with mUC, formalin-fixed paraffin-embedded tumor samples were evaluated with Dako 22C3 and Ventana SP263 PD-L1 immunohistochemistry assays.
The majority (29/32; 91%) of mRCC cases were concordant between assays. The majority (17/18; 94%) of mUC cases were also concordant between assays.
There was strong concordance between PD-L1 assays chosen for comparison in both mRCC and mUC, with similar performance characteristics. One limitation is the small number of cases in this study; larger comparison studies are needed for this biomarker in mRCC and mUC.
Clinical genitourinary cancer. 2020 Apr 10 [Epub ahead of print]
Landon C Brown, Jason Zhu, Matthew K Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, Jiaoti Huang, Wen-Chi Foo, Rajan T Gupta, Andrew J Armstrong, Daniel J George, Michael R Harrison, Tian Zhang
Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC., Department of Biostatistics and Bioinformatics, School of Medicine, Duke University, Durham, NC., Department of Pathology, School of Medicine, Duke University, Durham, NC., Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC; Department of Radiology, School of Medicine, Duke University, Durham, NC., Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/32482566
Go Beyond the Abstract and Read a Commentary by the Author